Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies

Neil M. D'Souza, Penny Fang, Jennifer Logan, Jinzhong Yang, Wen Jiang, Jing Li

Research output: Contribution to journalShort survey

17 Citations (Scopus)

Abstract

Malignancies of the central nervous system (CNS), particularly glioblastoma and brain metastases from a variety of disease sites, are difficult to treat despite advances in multimodality approaches consisting of surgery, chemotherapy, and radiation therapy (RT). Recent successes of immunotherapeutic strategies including immune checkpoint blockade (ICB) via anti-PD-1 and anti-CTLA-4 antibodies against aggressive cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, have presented an exciting opportunity to translate these strategies for CNS malignancies. Moreover, via both localized cytotoxicity and systemic proinflammatory effects, the role of RT in enhancing antitumor immune response and, therefore, promoting tumor control is being re-examined, with several preclinical and clinical studies demonstrating potential synergistic effect of RT with ICB in the treatment of primary and metastatic CNS tumors. In this review, we highlight the preclinical evidence supporting the immunomodulatory effect of RT and discuss the rationales for its combination with ICB to promote antitumor immune response. We then outline the current clinical experience of combining RT with ICB in the treatment of multiple primary and metastatic brain tumors. Finally, we review advances in characterizing and modifying tumor radioimmunotherapy responses using biomarkers and microRNA (miRNA) that may potentially be used to guide clinical decision-making in the near future.

Original languageEnglish (US)
Article number212
JournalFrontiers in Oncology
Volume6
Issue numberOCT
DOIs
StatePublished - Oct 7 2016
Externally publishedYes

Fingerprint

Radiotherapy
Central Nervous System
Neoplasms
Radioimmunotherapy
Central Nervous System Neoplasms
Glioblastoma
MicroRNAs
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Brain Neoplasms
Melanoma
Biomarkers
Neoplasm Metastasis
Drug Therapy
Antibodies
Brain
Therapeutics

Keywords

  • Brain metastases
  • Brain neoplasms
  • CTLA-4
  • Glioblastoma
  • Immune checkpoint blockade
  • Immunotherapy
  • PD-1
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies. / D'Souza, Neil M.; Fang, Penny; Logan, Jennifer; Yang, Jinzhong; Jiang, Wen; Li, Jing.

In: Frontiers in Oncology, Vol. 6, No. OCT, 212, 07.10.2016.

Research output: Contribution to journalShort survey

D'Souza, Neil M. ; Fang, Penny ; Logan, Jennifer ; Yang, Jinzhong ; Jiang, Wen ; Li, Jing. / Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies. In: Frontiers in Oncology. 2016 ; Vol. 6, No. OCT.
@article{f5edc890b4f14eb08439ef302c63ab45,
title = "Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies",
abstract = "Malignancies of the central nervous system (CNS), particularly glioblastoma and brain metastases from a variety of disease sites, are difficult to treat despite advances in multimodality approaches consisting of surgery, chemotherapy, and radiation therapy (RT). Recent successes of immunotherapeutic strategies including immune checkpoint blockade (ICB) via anti-PD-1 and anti-CTLA-4 antibodies against aggressive cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, have presented an exciting opportunity to translate these strategies for CNS malignancies. Moreover, via both localized cytotoxicity and systemic proinflammatory effects, the role of RT in enhancing antitumor immune response and, therefore, promoting tumor control is being re-examined, with several preclinical and clinical studies demonstrating potential synergistic effect of RT with ICB in the treatment of primary and metastatic CNS tumors. In this review, we highlight the preclinical evidence supporting the immunomodulatory effect of RT and discuss the rationales for its combination with ICB to promote antitumor immune response. We then outline the current clinical experience of combining RT with ICB in the treatment of multiple primary and metastatic brain tumors. Finally, we review advances in characterizing and modifying tumor radioimmunotherapy responses using biomarkers and microRNA (miRNA) that may potentially be used to guide clinical decision-making in the near future.",
keywords = "Brain metastases, Brain neoplasms, CTLA-4, Glioblastoma, Immune checkpoint blockade, Immunotherapy, PD-1, Radiotherapy",
author = "D'Souza, {Neil M.} and Penny Fang and Jennifer Logan and Jinzhong Yang and Wen Jiang and Jing Li",
year = "2016",
month = "10",
day = "7",
doi = "10.3389/fonc.2016.00212",
language = "English (US)",
volume = "6",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TY - JOUR

T1 - Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies

AU - D'Souza, Neil M.

AU - Fang, Penny

AU - Logan, Jennifer

AU - Yang, Jinzhong

AU - Jiang, Wen

AU - Li, Jing

PY - 2016/10/7

Y1 - 2016/10/7

N2 - Malignancies of the central nervous system (CNS), particularly glioblastoma and brain metastases from a variety of disease sites, are difficult to treat despite advances in multimodality approaches consisting of surgery, chemotherapy, and radiation therapy (RT). Recent successes of immunotherapeutic strategies including immune checkpoint blockade (ICB) via anti-PD-1 and anti-CTLA-4 antibodies against aggressive cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, have presented an exciting opportunity to translate these strategies for CNS malignancies. Moreover, via both localized cytotoxicity and systemic proinflammatory effects, the role of RT in enhancing antitumor immune response and, therefore, promoting tumor control is being re-examined, with several preclinical and clinical studies demonstrating potential synergistic effect of RT with ICB in the treatment of primary and metastatic CNS tumors. In this review, we highlight the preclinical evidence supporting the immunomodulatory effect of RT and discuss the rationales for its combination with ICB to promote antitumor immune response. We then outline the current clinical experience of combining RT with ICB in the treatment of multiple primary and metastatic brain tumors. Finally, we review advances in characterizing and modifying tumor radioimmunotherapy responses using biomarkers and microRNA (miRNA) that may potentially be used to guide clinical decision-making in the near future.

AB - Malignancies of the central nervous system (CNS), particularly glioblastoma and brain metastases from a variety of disease sites, are difficult to treat despite advances in multimodality approaches consisting of surgery, chemotherapy, and radiation therapy (RT). Recent successes of immunotherapeutic strategies including immune checkpoint blockade (ICB) via anti-PD-1 and anti-CTLA-4 antibodies against aggressive cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, have presented an exciting opportunity to translate these strategies for CNS malignancies. Moreover, via both localized cytotoxicity and systemic proinflammatory effects, the role of RT in enhancing antitumor immune response and, therefore, promoting tumor control is being re-examined, with several preclinical and clinical studies demonstrating potential synergistic effect of RT with ICB in the treatment of primary and metastatic CNS tumors. In this review, we highlight the preclinical evidence supporting the immunomodulatory effect of RT and discuss the rationales for its combination with ICB to promote antitumor immune response. We then outline the current clinical experience of combining RT with ICB in the treatment of multiple primary and metastatic brain tumors. Finally, we review advances in characterizing and modifying tumor radioimmunotherapy responses using biomarkers and microRNA (miRNA) that may potentially be used to guide clinical decision-making in the near future.

KW - Brain metastases

KW - Brain neoplasms

KW - CTLA-4

KW - Glioblastoma

KW - Immune checkpoint blockade

KW - Immunotherapy

KW - PD-1

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84997416758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997416758&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00212

DO - 10.3389/fonc.2016.00212

M3 - Short survey

C2 - 27774435

AN - SCOPUS:84997416758

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - OCT

M1 - 212

ER -